Inhibition of p53 can reduce hepatic triglyceride accumulation and lipotoxicity in a mouse model of non-alcoholic fatty liver disease, by reducing malonyl CoA and favoring the β-oxidation of fatty acids36. The gene discussed is TP53; the disease is metabolic dysfunction-associated steatotic liver disease.